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Manuscript length  
“It ain't what you don't know that gets you into trouble. It's what you know for sure that just 
ain't so” Mark Twain 
 
Most patients with heart disease develop heart failure before they die (1).  Medical articles 
usually portray heart failure as a disease that follows an inexorable downhill course unless 
suddenly interrupted by a fatal arrhythmia. This doom-laden narrative is usually reinforced 
by a series of “mantra” cut-and-pasted with little thought from a handful of original articles; 
“5.7 million Americans have heart failure” (defined exactly how and does no other 
nationality matter?); “the annual cost of heart failure is >$30 billion” (to whom?); “five-year 
survival is dismal” (for all patients and compared to what?); “morbidity and mortality remain 
unacceptably high” (exactly what would be acceptable?). Is this depressing depiction of heart 
failure really true, or has it become true only through frequent repetition and uncritical 
acceptance of received wisdom? Perhaps there might be a benefit in encouraging each other 
to be more optimistic for our patients? Who would want to invest (public) money in a lost 
cause; who would invest in failure? Patients are potentially the greatest resource (civil, 
political and medical) for improving healthcare but it is difficult to ask for a patient’s help if 
the doctor or nurse appear as harbingers of doom. Doctors must distinguish the “spin” of the 
lobbyists who believe that a message of fear and failure will obtain more resources for 
research and care from the clinical facts, which are not the same for all patients. Without facts 
how can we inform patients properly and consequently ensure that joint decisions in care are 
optimal. We require data and its correct interpretation. Time now to re-examine some of the 
shibboleths of heart failure.  
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In this edition of JACC-Heart Failure, Kalogeropoulos AP and colleagues provide us with 
some granular data, describing the incidence of progression from chronic stable (Stage C) to 
advanced (Stage D) heart failure in a substantial cohort of patients with a reduced left 
ventricular ejection fraction (HFrEF) in a high-quality academic health care system; Emory 
Health Care (2). There is no agreed definition of Stage D. In this report, it was based on 
medical judgement and/or the need for desperate measures (eg:- heart transplantation, left 
ventricular assist device (LVAD), inotropic therapy or palliative care). Many more patients 
might have been deemed to have progressed had another definition been used, such as 
recurrent hospitalization for heart failure. Age and co-morbidity may influence the use of 
treatments for advanced heart failure and therefore the nature of the patients reaching this 
endpoint.  
 
Why is this analysis important? Most pharmacological treatments for patients with chronic 
stable heart failure are generic and low-cost although many patients with HFrEF will require 
an implanted electrical device, which have substantial acquisition and maintenance costs. 
Most of the other costs of managing heart failure arise due to the inability to control 
congestion adequately resulting in hospitalization. The importance of “Stage D” is that it 
reflects intractable or recurrent congestion that is debilitating for patients and costly for 
health services. Controlling congestion and preventing sudden death are key therapeutic goals 
in the management of heart failure; indeed, poorly controlled congestion may be an important 
trigger for ventricular and supra-ventricular arrhythmias and sudden death.  
 
In the Emory cohort, the average patient age was 62 years, similar to that observed in many 
clinical trials but about 15 years younger than the epidemiological average. Many patients 
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were in New York Heart Association class III or IV at baseline and might have already been 
in Stage D. Younger age or referral patterns might account for the low rate of some co-
morbidities. Most patients were treated with ACE inhibitors and beta-blockers at the time of 
evaluation but only half of the patients had an implantable defibrillator. Presumably 
utilization of guideline-recommended therapies increased after initial patient-evaluation 
under the aegis of an expert health care system. Within three years about 25% of patients had 
died or progressed to Stage D; about 9% per year. This is remarkably similar to the rate of the 
primary outcome observed in the PARADIGM (Prospective Comparison of ARNI 
[Angiotensin Receptor–Neprilysin Inhibitor]with ACEI [Angiotensin-Converting–Enzyme 
Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial for 
patients with chronic stable heart failure assigned to sacubitril/valsartan. In the Emory cohort, 
the annual rate of progression to Stage D was 4.5% (but perhaps 6% if some grey-cases were 
included). Overall between 112 and 154 of 964 patients in this cohort progressed to Stage D 
over three years but only 21 of these received an LVAD and only seven a heart transplant. 
However, death prevented the possibility of reaching Stage D in a further 4.7% patients each 
year. Presumably most of these deaths were sudden, although some may have been non-
cardiovascular. More African-American patients progressed to Stage D but this may be 
because they were less likely to die before progressing. Progression to Stage D is, in some 
senses, good news because it is potentially reversible, unlike death. Prediction models for 
non-fatal outcomes in populations with a high mortality must be interpreted with extreme 
caution because there are two ways to prevent non-fatal events, only one of which is good 
news. Death may pre-empt progression or progression may be prevented by an effective 
therapeutic package. This is a major limitation of the risk-score presented in this paper. 
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Treatment with either beta-blockers or ACE inhibitors was strongly associated with lower 
mortality before reaching Stage D but not with progression to Stage D. This is best explained 
by a reduction in sudden death, since these agents are not known to reduce non-
cardiovascular mortality, due to or combined with a reduction in disease progression (3). 
Treatments that reduce sudden death but do not delay disease, as might be expected with an 
implantable defibrillator, may increase the number of patients in stage D and therefore the 
costs of healthcare. However, in the Emory cohort, implantable defibrillators were neither 
associated with a lower mortality prior to reaching stage D nor an increase in patients 
progressing to Stage D. Perhaps patients with implanted devices were at lower risk (younger 
age or milder symptoms) or had better pharmacological treatment. However, it is possible 
that sophisticated statistical analysis has disguised rather than illustrated the effect of 
treatment on outcomes. Simpler reporting of data is often better. Statistical models show only 
associations which often reflect variables that are surrogates for the true drivers of outcomes. 
Multivariable analyses should always be supported by expert clinical interpretation of an 
accompanying univariate analysis. Also, data-driven models should be compared to models 
based on clinical selection of key prognostic markers.  
 
Publishing from the same data-set, Kalogeropoulos AP and colleagues previously reported 
that 16.2% of patients with HFrEF had recovery of their left ventricular ejection fraction 
(LVEF) (4). The mortality at 3 years amongst these patients was 4.8% compared to 13.2% 
amongst those patients whose LVEF had not recovered. This is an important message 
corroborated by other reports. For instance, for patients aged <67 years randomized to cardiac 
resynchronization therapy in the CARE-HF (Cardiac Resynchronization – Heart Failure) 
study (New York Heart Association (NYHA) class III/IV heart failure with LVEF <35%), 
more than half were still alive 10 years later; many in NYHA class II (5). This much more 
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optimistic scenario is surely more appealing to patients, their advocacy groups, health 
professionals and research funders alike.  
 
In summary, Kalogeropoulos AP and colleagues have provided interesting analyses that 
provide new insights both into the progression of heart failure and its recovery. More trials 
are required to show that interventions such as inotropic therapy and LVADs lead to 
worthwhile improvements in wellbeing and outcome compared to expert pharmacological 
therapy in patients who have progressed to Stage D. However, it is strategically important 
that the heart failure community works harder on public relations; putting more emphasis on 
success and less on failure. Let’s dispel the narrative of gloom and doom. 
“Nothing succeeds like success” Sir Arthur Helps 
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Legend to Figure 
Title:- Forecast for Patients Age <70 years with Stable HFrEF in 2017. 
Blue arrows indicate current expectations for a patient aged <70 years with stable heart 
failure and mild-to-moderate symptoms managed in a good-quality, well-resourced 
cardiology service. Red crosses reflect the twin goals of preventing sudden death and disease 
progression. The red arrows represent the twin goals of reversing disease progression and 
increasing recovery after stabilization.  
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